SchizophreniaNCT01945333
Personalized and Scalable Cognitive Remediation Approaches
A study testing Cognitive remediation in people with Schizophrenia and Schizoaffective Disorder, run by New York State Psychiatric Institute at 5 sites in United States.
Trial summary
The purpose of this study is to develop and pilot test personalized and scalable approaches to Cognitive Remediation (CR) for schizophrenia and schizoaffective disorder. The intent is to more clearly define the therapeutic targets important to the facilitation of cognitive and functional improvement so that clinicians… Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Schizophrenia, Schizoaffective Disorder
- What is being tested?
- Cognitive remediation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 115 participants
- Where
- 5 sitesUnited States
- Study dates
- Sep 2013to 20 Mar 2019
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnostic and Statistical Manual-IV (DSM-IV) diagnosis of schizophrenia or schizoaffective disorder
- Age 18 to 65
- English speaking
- Psychiatrically stable, verified by current living/treatment status
Who cannot join
- Indication of mental retardation, determined by estimated IQ of less than 70
- Hearing or visual impairment that precludes completing assessments
- Neurologic illness that may affect brain physiology (e.g. Parkinson's, seizure disorder, epilepsy)
- Current substance dependence symptoms in the past 6 weeks
- Participation in cognitive remediation in the 12 months prior to study entry.
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
United States5 sites
Williamsburg Clinic
Brooklyn, New York, 11206
Institute for Community Living
Brooklyn, New York, 11207
Nyspi/ Cumc
New York, New York, 10032
The Bridge Inc
New York, New York, 10040
FEGS Bronx Mental Health Clinic
The Bronx, New York, 10467
About this study
The purpose of this study is to develop and pilot test personalized and scalable approaches to Cognitive Remediation (CR) for schizophrenia and schizoaffective disorder. The intent is to more clearly define the therapeutic targets important to the facilitation of cognitive and functional improvement so that clinicians know how to customize cognitive interventions and deliver treatment in a more effective, efficient and personally relevant manner.
Read the detailed description
There are three phases of this study.
Phase 1: Development and Adaptation. The goal of this phase is to adapt currently used computer based CR approaches to make them more personalized and scalable. We will create two CR interventions which differ in choice and pacing of the cognitive exercises. This phase is complete.
Phase 2: Open Trial and Intervention Refinement. The goal of this phase is to obtain quantitative and qualitative feedback on the acceptability and usability of the interventions from participants to inform further refinement of the assessment and treatment packages. We will recruit ten subjects from an outpatient psychiatric rehabilitation program in New York City. After determining study eligibility, individuals will complete a standardized neuropsychological battery for schizophrenia assessment, and a 5-minute Tone Matching Test to assess basic auditory processing. Participants will be randomly assigned to receive one of two intervention packages, developed in Phase 1. Each session includes 60 minutes of computer-based learning activities and a 15 minute therapist-led discussion that links the computer activities to cognition as applied to daily tasks and recovery goals. Participants will complete a total of 10 sessions attending 2-3 times weekly for 5 weeks. During each session, participants will be asked to keep a log of software used. At the conclusion of this abbreviated trial, the participants will participate in focus groups in which they will be asked to provide verbal feedback on how enjoyable, engaging, and useful they perceived the computer and discussion based exercises to be. Participants will be asked to provide verbal feedback on the assessment procedures. CR clinicians will join the research team to discuss participants' engagement and their experience with administering the Tone Matching Test and interventions. Qualitative data summarized from participant logs and focus groups will be considered by the research team to refine the assessment battery, treatment parameters, and rubric of learning exercises. This phase is complete.
Phase 3: Pilot Feasibility Trial. People with a diagnosis of schizophrenia or schizoaffective disorder may be referred by their treating clinician or may respond to posted advertisements to inquire about study participation. After being informed of study procedures, interested individuals will be asked to sign a consent form that documents willingness to participate in this study. Following informed consent, participants will be asked questions about demographic characteristics (e.g. age, education, employment), medication and psychosocial treatment status, psychiatric symptoms and symptoms severity, and will complete a brief assessment of estimated Intelligence. Those with an Intelligence Quotient (IQ) estimate below 70 or meeting substance dependence criteria at the time of evaluation will be exited from the study. In the same or second assessment session, participants will complete assessments of neuropsychological ability, current functioning, and motivation for treatment. Participants will then be randomly assigned to one of two treatment conditions named "Brain Basics" or "Brain Exercises".
Each treatment condition is structured in a group format of up to 5 participants. Both treatments use commercially available computer-based training software to exercise cognitive skills such as speed of processing, attention, working memory, and verbal memory. Both conditions will entail 50 minutes on the computer and 10 minutes group discussion. In the discussion, participants review the cognitive activities they are working on and how they will help them achieve their recovery goals. The treatment phase will consist of 30 separate sessions each 60 minutes in duration, administered 3 times a week over the course of a 10-week period. Participants will be re-tested on outcome measures approximately 1 week following end of treatment, and again 3 months later.
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Being tested
- Cognitive remediation
- Keywords
- Cognitive remediation, Schizophrenia, Schizoaffective disorder
- Medical subject headings
- Schizophrenia, Psychotic Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cognitive remediationBehavioural
Cognitive remediation sessions include working on computer based cognitive exercises and participating in a verbal discussion.
| Study group | Role | What they receive |
|---|---|---|
| Brain Basics for Impaired Tone Matchers | Active comparator | Cognitive remediation includes sensory processing training Receives: Behavioral: Cognitive remediation |
| Brain Basics for Intact Tone Matchers | Active comparator | Cognitive remediation includes sensory processing training Receives: Behavioral: Cognitive remediation |
| Brain Training for Impaired Tone Matcher | Active comparator | Cognitive remediation does not include sensory processing training Receives: Behavioral: Cognitive remediation |
| Brain Training for Intact Tone Matchers | Active comparator | Cognitive remediation does not include sensory processing training Receives: Behavioral: Cognitive remediation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility of Enrollment, Randomization and Retention
Feasibility is measured by enrollment, acceptability of randomization defined as number initiated allocated treatment, retention of subjects defined as number completed allocated treatment
Measured: Two years
Secondary outcomes (2)
Change in Neurocognition From Baseline to Treatment End-point
Change in neurocognition is calculated as the difference in the MATRICS Consensus Cognitive Battery Neurocognitive Composite Score between baseline and treatment end-point (10 weeks). The MATRICS Consensus Cognitive Battery Neurocognitive Composite T-Score is a scaled score calculated from the following component subscales: a) working memory; b) attention/vigilance; c) verbal learning; d) visual learning; e) processing speed; f) reasoning and problem solving. The mean T-score is 50 with a standard deviation of 10. Higher scores on the scale mean better outcomes. Higher change scores mean better outcomes.
Measured: 10 weeks
Change in Neurocognition From Baseline to 3-month Follow-up
Change in neurocognition is calculated as the difference in the MATRICS Consensus Cognitive Battery Neurocognitive Composite Score between baseline and 3-month follow-up (5.5 to 6 months). The MATRICS Consensus Cognitive Battery Neurocognitive Composite T-Score is a scaled score calculated from the following component subscales: a) working memory; b) attention/vigilance; c) verbal learning; d) visual learning; e) processing speed; f) reasoning and problem solving. The mean T-score is 50 with a standard deviation of 10. Higher scores on the scale mean better outcomes. Higher change scores mean better outcomes.
Measured: 5.5 to 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2013 (estimated)
- Study startSep 2013
- Primary completion2 Oct 2017
- Study completion20 Mar 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SchizophreniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 115 participants (actual)
Sponsor and investigators
- Lead sponsor
- New York State Psychiatric Institute
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH)
- Responsible party
- Principal investigator, Alice Medalia, New York State Psychiatric Institute
- Investigators
- Alice Medalia, PhD, Principal investigator, NYSPI
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01945333
- Sponsor's protocol ID
- #6721
- Other IDs
- 1R34MH100317-01
- Status last verified
- Jun 2026
- First submitted
- 13 Sep 2013
- Last updated
- 17 Jul 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- Individual data sharing
- No: This trial started enrolling participants before January 1, 2019.
Publications
Medalia A, Saperstein AM, Qian M, Javitt DC. Impact of baseline early auditory processing on response to cognitive remediation for schizophrenia. Schizophr Res. 2019 Jun;208:397-405. doi: 10.1016/j.schres.2019.01.012. Epub 2019 Jan 18.
PubMed 30665714
Study at a glance
From the registry record, last updated by the sponsor on 17 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Personalized and Scalable Cognitive Remediation Approaches
- ClinicalTrials.gov ID
- NCT01945333
- Acronym / sponsor ID
- #6721
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Keywords
- Cognitive remediation, Schizophrenia, Schizoaffective disorder
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 115 participants (actual)
- Lead sponsor
- New York State Psychiatric InstituteUniversity, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH)
- Study start
- Sep 2013
- Primary completion
- 2 Oct 2017 (actual)
- Study completion
- 20 Mar 2019 (actual)
- First posted
- 18 Sep 2013 (estimated)
- Results
- Posted 17 Jul 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to develop and pilot test personalized and scalable approaches to Cognitive Remediation (CR) for schizophrenia and schizoaffective disorder. The intent is to more clearly define the therapeutic targets important to the facilitation of cognitive and functional improvement so that clinicians know how to customize cognitive interventions and deliver treatment in a more effective, efficient and personally relevant manner.
Detailed description
There are three phases of this study.
Phase 1: Development and Adaptation. The goal of this phase is to adapt currently used computer based CR approaches to make them more personalized and scalable. We will create two CR interventions which differ in choice and pacing of the cognitive exercises. This phase is complete.
Phase 2: Open Trial and Intervention Refinement. The goal of this phase is to obtain quantitative and qualitative feedback on the acceptability and usability of the interventions from participants to inform further refinement of the assessment and treatment packages. We will recruit ten subjects from an outpatient psychiatric rehabilitation program in New York City. After determining study eligibility, individuals will complete a standardized neuropsychological battery for schizophrenia assessment, and a 5-minute Tone Matching Test to assess basic auditory processing. Participants will be randomly assigned to receive one of two intervention packages, developed in Phase 1. Each session includes 60 minutes of computer-based learning activities and a 15 minute therapist-led discussion that links the computer activities to cognition as applied to daily tasks and recovery goals. Participants will complete a total of 10 sessions attending 2-3 times weekly for 5 weeks. During each session, participants will be asked to keep a log of software used. At the conclusion of this abbreviated trial, the participants will participate in focus groups in which they will be asked to provide verbal feedback on how enjoyable, engaging, and useful they perceived the computer and discussion based exercises to be. Participants will be asked to provide verbal feedback on the assessment procedures. CR clinicians will join the research team to discuss participants' engagement and their experience with administering the Tone Matching Test and interventions. Qualitative data summarized from participant logs and focus groups will be considered by the research team to refine the assessment battery, treatment parameters, and rubric of learning exercises. This phase is complete.
Phase 3: Pilot Feasibility Trial. People with a diagnosis of schizophrenia or schizoaffective disorder may be referred by their treating clinician or may respond to posted advertisements to inquire about study participation. After being informed of study procedures, interested individuals will be asked to sign a consent form that documents willingness to participate in this study. Following informed consent, participants will be asked questions about demographic characteristics (e.g. age, education, employment), medication and psychosocial treatment status, psychiatric symptoms and symptoms severity, and will complete a brief assessment of estimated Intelligence. Those with an Intelligence Quotient (IQ) estimate below 70 or meeting substance dependence criteria at the time of evaluation will be exited from the study. In the same or second assessment session, participants will complete assessments of neuropsychological ability, current functioning, and motivation for treatment. Participants will then be randomly assigned to one of two treatment conditions named "Brain Basics" or "Brain Exercises".
Each treatment condition is structured in a group format of up to 5 participants. Both treatments use commercially available computer-based training software to exercise cognitive skills such as speed of processing, attention, working memory, and verbal memory. Both conditions will entail 50 minutes on the computer and 10 minutes group discussion. In the discussion, participants review the cognitive activities they are working on and how they will help them achieve their recovery goals. The treatment phase will consist of 30 separate sessions each 60 minutes in duration, administered 3 times a week over the course of a 10-week period. Participants will be re-tested on outcome measures approximately 1 week following end of treatment, and again 3 months later.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Brain Basics for Impaired Tone Matchers | Active comparator | Behavioral: Cognitive remediationCognitive remediation includes sensory processing training |
| Brain Basics for Intact Tone Matchers | Active comparator | Behavioral: Cognitive remediationCognitive remediation includes sensory processing training |
| Brain Training for Impaired Tone Matcher | Active comparator | Behavioral: Cognitive remediationCognitive remediation does not include sensory processing training |
| Brain Training for Intact Tone Matchers | Active comparator | Behavioral: Cognitive remediationCognitive remediation does not include sensory processing training |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Diagnostic and Statistical Manual-IV (DSM-IV) diagnosis of schizophrenia or schizoaffective disorder
- Age 18 to 65
- English speaking
- Psychiatrically stable, verified by current living/treatment status
Key exclusion criteria (5 listed)
- Indication of mental retardation, determined by estimated IQ of less than 70
- Hearing or visual impairment that precludes completing assessments
- Neurologic illness that may affect brain physiology (e.g. Parkinson's, seizure disorder, epilepsy)
- Current substance dependence symptoms in the past 6 weeks
- Participation in cognitive remediation in the 12 months prior to study entry.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cognitive remediationCognitive remediation sessions include working on computer based cognitive exercises and participating in a verbal discussion. | Behavioural | Brain Basics for Impaired Tone Matchers, Brain Basics for Intact Tone Matchers, Brain Training for Impaired Tone Matcher, Brain Training for Intact Tone Matchers |
Primary outcome
Feasibility of Enrollment, Randomization and Retention
Time frame: Two years
Feasibility is measured by enrollment, acceptability of randomization defined as number initiated allocated treatment, retention of subjects defined as number completed allocated treatment
2 secondary outcomes
Change in Neurocognition From Baseline to Treatment End-point
Time frame: 10 weeks
Change in Neurocognition From Baseline to 3-month Follow-up
Time frame: 5.5 to 6 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jul 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 30665714Medalia A, Saperstein AM, Qian M, Javitt DC. Impact of baseline early auditory processing on response to cognitive remediation for schizophrenia. Schizophr Res. 2019 Jun;208:397-405. doi: 10.1016/j.schres.2019.01.012. Epub 2019 Jan 18.
- Individual participant dataSharing planned: No. This trial started enrolling participants before January 1, 2019.
Related trials for Schizophrenia
RecruitingPhase 2
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
Schizophrenia
RecruitingPhase 3
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
Schizophrenia
Recruiting
Magnetic Seizure Therapy for Schizophrenia - Trial
Treatment Resistant Schizophrenia, Schizophrenia
Recruiting
Developing Biomarker-Supported Schizophrenia Spectrum Disorder (SSD) Prevention
Schizophrenia Spectrum Disorders (SSD)
RecruitingObservational study
Sensory Profile and Early Clinical Signs of Calm Room Users
Psychotic Disorders, Personality Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alice Medalia, PhD principal investigator
NYSPI
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cognitive remediation in people with Schizophrenia and Schizoaffective Disorder, run by New York State Psychiatric Institute at 5 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 17 Jul 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility of Enrollment, Randomization and Retention (time frame: Two years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01945333, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2026.